Merck (MRK) announced that the U.S. FDA has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy with or without cisplatin and then as a single agent.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck Animal Health receives EU CVMP positive opinion for NUMELVI
- Senators to propose ban on drug ads to consumers, WSJ reports
- Merck initiates Phase 3 study evaluating dengue vaccine candidate
- RFK Jr. names eight members to vaccine panel, WSJ reports
- RFK Jr. names new CDC vaccine advisory panel picks, STAT reports